title: Proteasome chymotrypsin-like activity in plasma as a useful marker for children with acute lymphoblastic leukemia.
abstract: BACKGROUND
  The proteasome chymotrypsin-like (Cht-L) activity was determined in plasma of children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in correlation to baseline leukocytosis, immunophenotype, LDH at the time of diagnosis and after remission induction.
  
  
  METHODS
  The activity was assayed using the fluorogenic peptide substrate in the presence of an artificial activator sodium dodecyl sulfate (SDS) in the plasma of healthy donors (n=25), acute lymphoblastic leukemia, ALL (n=95) and AML (n=17) patients.
  
  
  RESULTS
  As compared to healthy subjects, the plasma proteasome ChT-L activity was significantly increased (p=0.001) in ALL patients prior to treatment, especially in those with T-ALL immunophenotype and with high LDH activity. Similarly, in AML patients the plasma proteasome ChT-L activity was elevated (p=0.001). Following remission-inducing chemotherapy, the activity of the ChT-L proteasome was significantly reduced both in ALL and AML patients.
  
  
  CONCLUSIONS
  Plasma proteasome ChT-L activity may serve as an additional marker in monitoring anticancer therapy.
authors: Department of Pediatric Oncology and Hematology, Medical University of Bialystok, ul. Waszyngtona 17, Bialystok, Poland. rybak@umwb.edu.pl
authors: Maryna
authors: M
authors: Krawczuk-Rybak
authors: Elzbieta
authors: E
authors: Leszczynska
authors: Iwona
authors: I
authors: Malinowska
authors: Michal
authors: M
authors: Matysiak
authors: Halina
authors: H
authors: Ostrowska
mesh_terms: D000293:Adolescent; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D053818:Chymases / Q000097:blood*; D005260:Female; D006801:Humans; D007223:Infant; D007770:L-Lactate Dehydrogenase / Q000097:blood; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy / Q000201:enzymology; D007958:Leukocyte Count; D007964:Leukocytosis; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology; D011239:Prednisolone / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000097:blood*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D011239:Prednisolone; D007770:L-Lactate Dehydrogenase; D053818:Chymases; D046988:Proteasome Endopeptidase Complex